What is Tirzepatide?
Tirzepatide (LY3298176) is a dual-agonist research peptide targeting both the GLP-1 and GIP receptors. The dual-receptor mechanism is studied for its compounding effects on appetite signaling, gastric emptying, and post-prandial glucose regulation — and has driven significant body-weight reductions in published clinical-research settings.
Tirzepatide remains one of the most heavily-studied incretin-class research compounds and forms a reference point for newer multi-agonist peptides such as Retatrutide.
How it's studied — mechanism
Tirzepatide engages two complementary incretin receptors:
- GLP-1 receptor — satiety, delayed gastric emptying, modulated insulin secretion
- GIP receptor — incretin amplification, lipid-utilization pathways
The combined profile is studied for its capacity to amplify the metabolic effects of GLP-1 mono-agonism while reducing the GI-side-effect profile typically seen with high-dose GLP-1 alone.
Amino acid sequence
33-aa modified peptide (His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-…)Published research
The following primary sources are provided to support qualified-researcher review. Inclusion is for reference only and does not constitute medical advice or therapeutic claim.